Nov. 29, 2022
WASHINGTON — PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics, and for fighting even the tiniest of policy changes.
The pharmaceutical industry’s lobbying arm raised hell, for example, when lawmakers asked it to cover a slightly larger share of seniors’ drug costs. It spent years refusing to concede even minimal tweaks to an obscure bill related to generic competition.
Over the last year, however, something changed. PhRMA, once a titanic lobbying powerhouse, lost its edge.
About the Author
Create a display name to comment
This name will appear with your comment
